Latest insights

As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
  • Fixed Income, Charudatta Shende

    Bond market opportunities: The Return of Slope

    The global rates landscape is entering a decisive new phase as the long-standing flatness of yield curves gives way to steepness that has not been seen since 2011. The term premium, the additional interest by bondholders investing in longer-dated bonds versus short-term bonds, is back after an absence of many years.
  • ESG, SRI

    Active Ownership: Persistence Pays

    If some elements of our annual 2024 Annual Engagement and Voting Review sound familiar, that’s no coincidence. To maximize our impact, we focus on long-term core topics. Engagement and voting are central to our investment process, extending beyond the important responsibility of the investments we already hold.
87 results found
  • ESG, SRI
Show me
  • Topic
  • Theme
  • Publication
  • Expert
Show me
  • Topic
  • Theme
  • Publication
from
  • Expert
87 results found
  • ESG, SRI
Research Paper, Alix Chosson, Elouan Heurard, ESG, SRI, Biodiversity

Can We Assess Companies’ Ecological Debt? And How?

While, according to the World Economic Forum, half of the global GDP is dependent on nature, biodiversity is experiencing an extinction that challenges the resilience of our economies. Deterioration of air, water and soil quality, decline in ecosystem services such as pollination: the physical impacts of this loss of biodiversity are already putting our economies under pressure.
Healthcare, ESG, SRI

Why healthcare, why now?

On Tuesday, September 30, the pharmaceutical industry issued its first formal response to President Trump’s recent letter on drug pricing, announcing a deal between Pfizer and the US administration.
ESG, SRI, Oncology, Healthcare

From uncertainty to growth: why invest in healthcare?

As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
Ken Van Weyenberg, Oncology, ESG, SRI, Healthcare

Why oncology remains a key investment opportunity

The investment landscape is marked by persistent macroeconomic uncertainties, uneven growth, and heightened geopolitical risks. Despite attractive earnings growth, healthcare has also been under pressure due to regulatory restructuring, drug pricing debates, budget constraints, and tariff concerns.
Research Paper, Climate Action, ESG, SRI, Alix Chosson

Net Zero Progress Report

We promised you transparency. For a comprehensive discussion of our efforts and results, see our [annual] Net Zero Progress Report 2024. We frequently say that it is not just the carbon target, but the path to that target which affects the damage along the way. In this spirit, we share with you along the way our milestones for the four pillars of our Net Zero strategy.
ESG, SRI

Active Ownership: Persistence Pays

If some elements of our annual 2024 Annual Engagement and Voting Review sound familiar, that’s no coincidence. To maximize our impact, we focus on long-term core topics. Engagement and voting are central to our investment process, extending beyond the important responsibility of the investments we already hold.
Research Paper, Marie Niemczyk, Jorick Liebrand, ESG, SRI, AI

AI Through the ESG Lens: Tackling Risks and Opportunities

Is the Artificial Intelligence (AI) revolution unstoppable? With lightning speed, AI is reshaping industries, unlocking economic value, driving positive environmental impact, helping address social challenges – and additionally, offering compelling investment opportunities.

Find it fast

Get information faster with a single click

Get insights straight to your inbox